Streetbeat News

SNES

SenesTech, Inc.

https://www.senestech.com

Industry

Chemicals - Specialty

SenesTech, Inc. develops a technology for managing animal pest populations through fertility control. It offers ContraPest, a liquid bait that limits reproduction of male and female rats. The company was incorporated in 2004 and is headquartered in Phoenix, Arizona.

Open

2.30

Mkt cap

2.3M

Volume

5.6K

High

2.32

P/E Ratio

0.02

52-wk high

30.80

Low

2.19

Div yield

N/A

52-wk low

1.90

SenesTech, Inc. reported its third quarter 2024 financial results, highlighting a 51% increase in revenue to $1.4 million for the first nine months of 2024 compared to the same period in 2023.

Portfolio Pulse from

November 12, 2024 | 9:15 pm

SenesTech, Inc. has expanded the distribution of its rodent birth control products, Evolve™ Rat and Evolve™ Mouse, by launching them on Walmart Marketplace. This move significantly increases the market reach of SenesTech's products.

Portfolio Pulse from

November 12, 2024 | 2:15 pm

SenesTech, Inc. (NASDAQ: SNES) will release its Q3 2024 financial results on November 12, 2024, after market close, followed by a conference call at 5:00 pm ET to discuss the results.

Portfolio Pulse from

November 05, 2024 | 9:30 pm

The article reports on the after-market session movements of various healthcare stocks. Notable gainers include SenesTech, Venus Concept, and AtriCure, while Tyra Biosciences, DaVita, and 10x Genomics were among the losers. AtriCure, DaVita, and 10x Genomics released their Q3 earnings.

Portfolio Pulse from Benzinga Insights

October 29, 2024 | 8:31 pm

SenesTech (NASDAQ:SNES) reported Q2 2024 GAAP EPS of $(3.08), beating the estimate of $(3.20). However, sales of $459,000 missed the $485,000 estimate. Sales increased by 50.49% compared to the same period last year.